A Phase II Trial of Interferon Alpha-2a and Carboplatin in Patients with Advanced Malignant Mesothelioma

References

• Antman K. Current concepts: malignant mesothelioma. N Engl J Med 1980; 303: 200–202
   PubMed Web of Science ®Google Scholar
• Alberts A S, Falkson G, Goedhals L, et al. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol 1988; 6: 527–535
   PubMed Web of Science ®Google Scholar
• Ong S T, Vogelzang N J. Chemotherapy in malignant pleural mesothelioma: a review. J CIin Oncol 1996; 14: 1007–1017
   PubMed Web of Science ®Google Scholar
• Chahinian A P, Pajak T F, Holland J F, et al. Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann Intern Med 1982; 96: 746–755
   PubMed Web of Science ®Google Scholar
• Connelly R R, Spirtas R, Myers M H, et al. Demographic patterns for mesothelioma in the United States. J Natl Cancer Inst 1996; 78: 1053–1060
   Google Scholar
• Rusch V W, Piantadose S, Holmes E C. The role of extrapleural pneumonectomy in malignant mesothelioma: a lung cancer study group trial. J Thorac Cardiovasc Surg 1991; 102: 1–9
   PubMed Web of Science ®Google Scholar
• Kutcher G J, Kestler R T, Greenblatt D, et al. Technique for external beam treatment for mesothelioma. Int J Radiat Oncol Biol Phys 1987; 13: 1747–1752
   PubMed Web of Science ®Google Scholar
• Sugarbaker D, Harpole D, Healey E, et al. Multimodality treatment of malignant pleural mesothelioma: results in 94 consecutive patients [abstract]. Proc Am Soc Clin Oncol 1995; 14: 1083
   Google Scholar
• Aisner J, Wiernik P H. Chemotherapy in the treatment of malignant mesothelioma. Semin Oncol 1981; 8: 335–343
   PubMed Web of Science ®Google Scholar
• Zidar B L, Green S, Pierce H I, et al. A phase II evaluation of cis-platin in diffuse malignant mesothelioma. A Southwest Oncology Group study. Invest New Drugs 1988; 6: 223–226
   PubMed Web of Science ®Google Scholar
• Mintzer D M, Kelsen D, Frimmer D, et al. Phase II trial of high dose cisplatin in patients with malignant mesothelioma. Cancer Treat Rep 1985; 69: 711–712
   PubMedGoogle Scholar
• Solheim O P, Saeter G, Finnanger A M, et al. High dose methotrexate in the treatment of malignant mesothelioma of the pleura. Br J Cancer 1992; 65: 956–960
   PubMed Web of Science ®Google Scholar
• Raghavan D, Giansoutsos P, Bishop J, et al. Phase II trial of car-boplatin in the treatment of patients with mesothelioma. J Clin Oncol 1990; 8: 151–154
   PubMedGoogle Scholar
• Mbidde E K, Harland S J, Calvert A H, et al. Phase II trial of car-boplatin in the treatment of patients with mesothelioma. Cancer Chemother Pharmacol 1986; 18: 284–285
   PubMed Web of Science ®Google Scholar
• Vogelzang N J, Goutsou M, Corson J M, et al. Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B. Cancer Chemother Pharmacol 1990; 27: 239–242
   PubMed Web of Science ®Google Scholar
• Mbidde E K, Smith I E, Harland S J. Phase II trial of carboplatin in the treatment of patients with mesothelioma. Br J Cancer 1986; 54: 215–216
   Web of Science ®Google Scholar
• Ardizzoni A, Pennuci M C, Castagneto B, et al. Recombinant in-terferon alpha-2b in the treatment of diffuse pleural malignant mesothelioma. Am J Clin Oncol 1994; 17: 80–82
   PubMed Web of Science ®Google Scholar
• Christmas T I, Musk A W, Robinson B WS. Phase II study of recombinant human interferon alpha therapy in malignant pleural mesothelioma [abstract]. Proc Am Assoc Cancer Res 1990; 31: 283
   Google Scholar
• Sklarin N T, Chahinian A P, Feuer E J, et al. Augmentation of activity of cis-diamminedichloroplatinum (CDDP) and mitornycin C by interferon in human mesothelioma xenografts in nude mice. Cancer Res 1988; 48: 64–67
   PubMed Web of Science ®Google Scholar
• Wadler S, Schwartz E L. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 1990; 50: 2473–2486
   Google Scholar
• Miller A B, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47: 207–214
   PubMed Web of Science ®Google Scholar
• Gehan E A. The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J Chronic Dis 1961; 13: 346–353
   PubMedGoogle Scholar
• Ruffie P, Feld R, Minkin S, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol 1989; 7: 1157–1168
   PubMed Web of Science ®Google Scholar
• Herndon J E, Green M R, Chahinian A P, et al. Factors predictive of survival among 337 patients with malignant mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B [abstract]. Proc Am Soc Clin Oncol 1996; 15: 452
   Google Scholar
• Adams V I, Unni K K, Muhn J R, et al. Diffuse malignant mesothelioma of the pleura. Diagnosis and survival in 92 cases. Cancer 1986; 58: 1540–1551
   PubMed Web of Science ®Google Scholar
• Lerner H J, Schoenfeld D A, Martin A, et al. Malignant mesothelioma: the Eastern Cooperative Oncology Group experience. Cancer 1983; 52: 1981–1985
   PubMed Web of Science ®Google Scholar
• Soulie P., Ruffie P, Trandafir L, et al. Combined systemic che-moimmunotherapy in advanced malignant mesothelioma: report of a phase I-II study of weekly cisplatin/ interferon alpha-2a. J Clin Oncol 1996; 14: 878–885
   PubMed Web of Science ®Google Scholar